Notice of Results

Investor Results Presentation

EKF Diagnostics Holdings plc (AIM: EKF) previously announced that it proposed to release its preliminary results for the year ended 31 December 2015 on Tuesday 5 April 2016. This has been postponed by a week to Tuesday 12 April 2016.

Investor presentation

A briefing for all investors will take place on Tuesday 12 April 2016 at Panmure's office, One New change, EC4M 9AF from 5pm for a 5.15pm start, and will be followed by drinks.

If you would like to register for the investor presentation, or require further information, please contact Lianne Cawthorne at Walbrook PR on 020 7933 8780 or email

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

US FDA approval for Quo-Test analyser

EKF Diagnostics announces that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use in a clinical laboratory setting.

Update on McKesson US distribution agreement for DiaSpect Tm

EKF announces the full launch of the McKesson Consult^® Hb analyzer in the US in February.

Trading update

EKF Diagnostics provides shareholders with the following update on current trading.

Update regarding planned change of nominated adviser

EKF Diagnostics Holdings plc announces that, further to the announcement on 1 November regarding its planned appointment of a new nominated adviser following the admission of Renalytix AI PLC (“RenalytixAI”) to trading on AIM, the boards of EKF and RenalytixAI have now agreed a different resolution to the requirement for one of the two companies to appoint a new nominated adviser.

PDMR dealing

EKF Diagnostics announces that on 19 December 2018, the Company was notified by Mike Salter (President, Americas) that he has today purchased 125,000 ordinary shares.